相关实验视频
Updated: Jun 17, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
美国卫生系统中-葡萄糖共运输体2抑制剂的处方模式
Jung-Im Shin1, Yunwen Xu1, Alexander R Chang2
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Journal of the American College of Cardiology
|August 14, 2024
概括
对于许多患者,建议使用-葡萄糖共运输体2 (SGLT2) 抑制剂,但处方率仍然很低. 这项研究强调了需要进行干预措施,以增加这些指南推的治疗方法的采用率.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 建议用于糖尿病,心力衰竭 (HF) 和慢性病 (CKD) 的患者使用-葡萄糖共运输体2 (SGLT2) 抑制剂.
- 这些药物可以减少HF住院,心血管事件和CKD进展.
- 他们对特定患者群体进行了1a类推,包括那些患有严重白蛋白尿或高血压患者,无论糖尿病状况如何.
研究的目的:
- 评估1a类推患者的SGLT2抑制剂的处方率.
- 根据糖尿病状况和推标准来描述SGLT2抑制剂的处方模式.
主要方法:
- 分析了来自美国28个卫生系统的3,189,827名成年人 (2022年4月至2023年3月).
- 根据糖尿病存在和1a类推状态对SGLT2抑制剂处方率的分层评估.
- 根据医生专业和卫生系统特征检查了处方模式.
主要成果:
- 在716,387名患有糖尿病的成年人中,只有11.9%的人接受了SGLT2抑制剂的处方.
- 在2,473,440名没有糖尿病但有1a类推的成年人中,3.1%的人获得了处方.
- 没有一个卫生系统超过25%的处方率符合条件的患者;内科医生/家庭医生是糖尿病患者的更常见的处方者,而专家则为没有糖尿病患者领导.
结论:
- 在1a类推患者中,SGLT2抑制剂的处方率在美国很低.
- 干预措施是必要的,以改善指南推的SGLT2抑制剂治疗的采用.
- 处方模式因患者的糖尿病状况和医生的专业而异.
相关概念视频
Secondary Active Transport
118.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
118.7K
Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Oral Hypoglycemic Agents: Glinides
149
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
149
Glucagon-like Receptor Agonists
308
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
308
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Oral Hypoglycemic Agents: Sulfonylureas
197
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
197

